[1] 张莉，冯瑞梅，胡尚英，等．细胞学检测为非典型鳞状细胞且人乳头瘤病毒阴性妇女的宫颈癌患病风险评估［J］．中华流行病学杂志，2016，37(6):801 － 804.[2] 何文刚，赵骏，黄守杰，等. 重组人乳头瘤病毒疫苗临床评价研究进展［J］．中华流行病学杂志，2016，37(6):904 － 908.[3] Lu L, Yang X, Jiang SB, et al. Chemically modified bovine beta-lactoglobulin inhibits human papillomavirus infection [J]. Microb Infect, 2013, 15(6-7): 506-510.[4] Wu Z, Qin Y, Yu L, et al. The association between human papillomavirus (HPV) 16, HPV18, and other HR-HPV viral load and the histological classification of cervical lesions: Results from a large-scale cross-sectional study [J]. J Med Virol, 2016. [Epub ahead of print].[5] 王小红，钱艺美，缪铃，等 . 高危型 HPVE6/ E7mRNA 与宫颈癌相 关性分析［ J］．流行病学[5] 王小红，钱艺美，缪铃，等. 高危型 HPV E6/E7 mRNA 与宫颈癌相关性分析 [J].流行病学杂志，2016, 37(7): 1003-1005. ( 注：原文期刊名有误，应为《中华流行病学杂志》或核实正确期刊名)[6] Zeng Z, Yang H, Li Z, et al. Prevalence and Genotype Distribution of HPV Infection in China: Analysis of 51, 345 HPV Genotyping Results from China’s Largest CAP Certified Laboratory [J]. J Cancer, 2016, 7(9): 1037-1043. ( 注：补充了卷期号7(9))[7] Ma’som M, Bhoo-Pathy N, Nasir NH, et al. Attitudes and factors affecting acceptability of self-administered cervicovaginal sampling for human papillomavirus (HPV)genotyping as an alternative to Pap testing among multiethnic Malaysian women [J]. BMJ Open, 2016, 6(8): e011022.[8] Guo XT, Qiu LX, Wang Y, et al. A randomized open-label clinical trial of an anti-HPV biological dressing (JB01-BD) administered intravaginally to treat high-risk HPV infection [J]. Microbes Infect, 2016, 18(2): 148-152.[9] Guo X, Qiu L, Wang Y, et al. Safety evaluation of chemically modified beta-lactoglobulin administered intravaginally [J]. J Med Virol, 2015, 87(8): 1406-1412. ( 注：补充了卷期号87(8) 和页码，Epub ahead of print 通常有后续正式发表)[10] 刘彬，吴泽妮，刘潇阳，等. 人乳头瘤病毒与子宫颈腺癌病因关系研究 [J]. 中华肿瘤杂志，2016, 38(4): 277-282.